De-Risking Healthcare Technology: Why Product Discovery Saves 10x What It Costs

Last updated: July 2026
By: Kevin Yamazaki, Partner and CEO at Sidebench

Product Discovery, Solution Design, and Technical Architecture is the short, structured phase before a healthcare build where you find the wrong assumptions while they’re still cheap to fix, and where you put a working prototype in front of real users before anyone writes production code. In our experience the decisions that break a healthcare product are almost never caught in the code. They’re caught, or missed, in the 6 to 12 weeks before the code starts. Skip that phase and the same decisions surface mid-build, where they cost roughly 10 times more to unwind, or post-launch with patients already on the platform, where they cost more again.

This is the read we give every founder, health-system innovation lead, and product executive who arrives at Sidebench ready to build. Most arrive convinced the risk lives in the engineering. It rarely does. The engineering is tractable. The risk lives in the decisions made before engineering starts: which integrations are actually required, whether the product is a regulated device, who owns scope, how the data has to flow, and whether the workflow you designed is one a clinician or a patient will actually use. Discovery is where those get settled. This article covers what discovery de-risks, what it produces, and, honestly, when you don’t need it.

What Product Discovery actually is in healthcare

Product Discovery is a focused pre-build engagement that pressure-tests the riskiest assumptions in a healthcare product before a line of production code is written. It is not a sales artifact and it is not a slide deck. It produces working design, tested with the people who will use it, alongside the technical and regulatory decisions that determine whether that design can ship. It is the work of turning “we want to build X” into “here is exactly what X requires, here is what will break it, and here is the sequence that gets it shipped.”

In a healthcare context, discovery covers the things a generic product workshop skips: the regulatory posture, the integration surface, the patient-identity and data model, the clinical workflow the product has to survive, the designed experience tested with the people expected to use it, and the ownership structure that decides whether the build ships or stalls. Consumer-software discovery can get away with “who’s the user and what’s the job.” Healthcare discovery has to add “which regulator cares, which EHR gates the launch, and whose sign-off is on the critical path.”

The output is a set of decisions a sponsor can take to a board, a budget committee, or a vendor selection, with the risks named and priced, plus the designs and the prototype that show what is being funded.

Why it matters more in 2026, not less

The cheaper it has become to produce a prototype, the more expensive it has become to skip discovery. In 2026 anyone can stand up a working-looking healthcare app in a weekend with AI coding tools. The demo is not the hard part anymore. The hard part is everything a demo hides: HIPAA architecture, the integration that a real customer requires, the regulatory line the product crosses, and the failure modes that only show up under real patient load.

Three forces make this year different.

The first is the AI-built prototype. Founders now walk in with a vibe-coded MVP that looks finished and assume they’re most of the way there. They’re usually at the start. A prototype that reads patient data on a phone is a different system from one that transmits it off-device, persists it to a server, and satisfies the technical safeguards under 45 CFR 164.312. The gap between the two is exactly the gap discovery measures.

The second is the regulatory line, which moved this year. The FDA has now authorized more than 1,000 AI-enabled medical devices, and recent FDA guidance (2025 and 2026) has addressed AI change-control, clinical decision support, and quality-management alignment with international standards (FDA Digital Health guidance). Whether your product is Software as a Medical Device is not a detail you discover after the build. It reshapes the build. Finding out in month 5 that you crossed the SaMD line is one of the most expensive surprises in this industry.

The third is that HIPAA has become a due-diligence gate rather than a launch checklist. Healthcare investors and strategic buyers now expect to see a completed security risk assessment with documented findings before they write a check or sign a deal. A product that treated compliance as a phase-two problem shows up as a red flag in diligence. Discovery is where you decide to build that in from day one instead.

None of this argues for more process. It argues for the right 6 to 12 weeks up front, so the 12 months after don’t get spent on rework.

The 10x rule: why a wrong decision gets more expensive the longer it survives

A wrong architectural or product decision costs roughly 10 times more to fix once the build is underway than it does in discovery, and more again once the product is in production with patients on it. That is not a Sidebench metric; it is the well-documented pattern in software engineering: the cost to correct a decision grows by roughly an order of magnitude at each stage it goes undetected. The pattern holds harder in healthcare, where the later stages involve real clinical data and real regulatory exposure.

The mechanism is simple. A wrong assumption caught in discovery costs a conversation and a revised plan. The same assumption caught mid-build costs the code already written on top of it, the schema already shipped, and the team’s time to unwind and rebuild. The same assumption caught after launch costs all of that plus a live migration, a customer already onboarded, and, in healthcare, an audit trail that now has to account for the change.

The single most consistent version of this we see is the integration assumption. A team scopes a build assuming a specific EHR data flow is available, straightforward, or fast. It isn’t. On one Epic-integrated engagement, the assumption that would have been a footnote in discovery would have cost roughly 10 times more to find during development, because by then the product was built around it. That ratio is the whole argument for discovery in one number. The exact multiple varies. The direction never does: the cost of a wrong foundation scales with how late you catch it.

The five decisions discovery de-risks

Five decisions cause most of the expensive surprises in healthcare builds. Each looks like a technical decision and is actually a business decision in disguise. Discovery is where you make them on purpose instead of by default.

Integration. Which integration does v1 actually require, and which is a v2 nice-to-have dressed up as mandatory? Teams routinely scope a full bidirectional EHR integration when a read-only feed would ship the product, or assume a legacy data source is an asset when it’s a constraint. The integration decision sets the timeline more than any other, because the binding constraint is usually the customer’s own security review and change-control queue, not your engineering.

Regulatory posture. Is the product Software as a Medical Device, or isn’t it? Does it make a diagnostic, treatment, or monitoring claim that pulls it into FDA scope? The answer changes the documentation burden, the testing regime, and the release process from the first commit. This is the decision teams most want to defer and can least afford to.

Scope and ownership. What is the smallest version of the product that, if it works, proves the venture is worth scaling, and who owns the roadmap with the authority to cut scope? The most reliable failure mode we see is organizational. It shows up as 3 people each holding a third of a decision: a sponsor who controls budget but not roadmap, a clinical lead who controls workflow but not product, an IT lead who controls integration but not experience. That’s 6 months of stall, every time.

Data and identity architecture. How does data flow from the source, through the pipeline, into the clinical or member experience, and how do you match a patient across systems and keep the match stable? Patient identity is the layer teams underbuild most often, and the consequences land months after launch, in the form of data teams can’t trust and clinicians who stop using the product.

Experience and workflow. Does the workflow you designed survive contact with the people who have to run it, at volume, on a bad day? This is the decision teams most often leave to the build, and it is the one that decides adoption. A product can be compliant, integrated, and correctly scoped and still fail because the intake nurse needs 9 clicks where the paper form took 2. You settle this by designing the workflow and testing it with real users, not by assuming it.

Get these five right in discovery and the build is an execution problem. Get them wrong and the build becomes an archaeology problem.

Prototype first, then test with real users

It’s significantly easier to change pixels than code.

A prototype is a working model of the experience, built in days rather than months, that a clinician or a patient can hold and try. Every problem it surfaces is a problem you fix before the schema, the integration, and the code are built on top of it, when the fix still costs a design revision.

Discovery should produce an interactive prototype, not a static wireframe pack. It moves, it responds, and it covers the workflow end to end: the intake, the handoff, the exception path someone hits on a bad day. That is what makes user testing worth running. Ask someone to react to a flat screen and you get an opinion. Give them a working flow and a real task and you get behavior.

You do not need a large sample. A handful of the right users surfaces most of what matters, and the right users in healthcare are rarely the ones who volunteer: the nurse on the night shift, the patient with low digital literacy, the intake coordinator running a workaround nobody documented. Watching them work through a prototype shows you the step people skip, the screen where they stop, and the word that means one thing in a product meeting and something else at the bedside.

What comes back from those sessions changes the product while changing it is still cheap. A step gets removed. Two screens collapse into one. A field nobody could reliably answer gets dropped, which quietly removes an integration from the v1 scope. That last one is the pattern worth noticing: user testing improves the experience and cuts the build at the same time.

Then the design has to be finished properly. Discovery ends with assets a development team can build from without a translation layer: full UI for the v1 scope, states and edge cases, the component library behind them, and specs annotated against the requirements. Ambiguity that survives into a sprint gets resolved by a developer guessing at 4pm on a Thursday. The reason to finish the design in discovery is that nobody has to guess.

Discovery vs jumping straight to build

Skipping discovery doesn’t remove the risky decisions. It moves them downstream, where they cost more to fix. The table below is the same healthcare build run two ways: straight to code, or through a short discovery phase first. The difference shows up in cost, timeline, and what a sponsor can put in front of a board.

The honest tradeoff: discovery adds 6 to 12 weeks before the build starts. It’s the cheapest 6 to 12 weeks in the whole program.

What a discovery engagement actually produces

A healthcare discovery engagement produces a build-ready package, not a single document. The sponsor gets the decisions and the evidence, with the risks named, sized, and sequenced. The development team gets everything it needs to start building.

Depending on the scale, that means some or all of the following:

• Product requirements. The v1 feature set, the user stories behind it, and the acceptance criteria that say when each one is done.
• Technical requirements and architecture. The stack, the environments, the integration contracts, and the non-functional requirements the build has to hold to.
• Full UI designs. Every screen in the v1 scope, with states, edge cases, and the component library behind them, annotated for the team that builds it.
• An interactive prototype. A working model of the workflow, tested with real users, that shows what is being funded before it is funded.
• An integration risk audit. Which integrations v1 requires, what each one gates, and where the customer-side queues sit on the timeline.
• A regulatory posture read. Whether the product is SaMD, what claims pull it into scope, and what the documentation burden looks like if it does.
• A prioritized scope and a named owner. The smallest credible v1, the outcome that proves it, and a RACI that puts one person’s name on the roadmap.
• A data and identity architecture proposal. How data flows, how patients are matched, and where the enterprise master patient index layer belongs.
• An implementation plan, development budget, and timeline. What gets built, in what order, by whom, at what indicative cost, with the risks priced.
• A build-or-translate recommendation. An honest read on whether to build, buy, or partner for each piece.

Sidebench runs this as a discovery and solution-design engagement, typically 6 to 12 weeks depending on how complex the integration and regulatory surface is. It ends with a decision the sponsor can act on and a package the build team can start from on day one.

When you don’t need discovery

Not every build needs a discovery phase, and it’s worth being honest about that. There is really one case: you already have documented product requirements, technical documentation, and a finished design that real users have tested. If all three exist and hold up to scrutiny, you have what discovery produces, and buying it again is waste.

That case is rarer than teams assume. And a team that genuinely has all three needs a development team to execute a settled plan, which is a different engagement from the one this article describes. Sidebench is useful when the plan is not settled yet.

Discovery earns its cost when at least one of these is true: the integration surface is non-trivial (EHR, multi-vendor, or legacy data), the regulatory line is unclear, the scope keeps expanding, the workflow has not been tested with the people expected to use it, or the decision rights are split across people who don’t yet agree. If none of those apply, skip it and build. A partner who sells you discovery you don’t need is a partner to be suspicious of.

Discovery exists to keep the 12 months after it from being spent discovering, expensively, what a focused few weeks would have surfaced for a fraction of the cost.

Where Sidebench has run this

Sidebench has run pre-build discovery across health systems, longevity ventures, diagnostics providers, and behavioral health, and the pattern holds across all of them: the decisions that determined whether v1 shipped were made before development, not during it.

Hoag Compass 3.0 shipped a deep Epic integration inside a subscription preventive medicine experience, and the build absorbed real-world latency the sandbox never predicted. A longevity client (anonymized) built a cardio-cognitive prevention product on an AthenaOne, Oura, and Dexcom stack, where the custom data pipeline was the real engineering, not the app. A national diagnostics provider engaged us on the pre-build strategy for extending into longevity, where the existing imaging history was the moat, if the integration was scoped correctly. Different products, same lesson: the architecture and ownership decisions made in discovery are what let the build move fast.

Frequently Asked Questions

What is Product Discovery in healthcare software?

Product Discovery is a focused pre-build engagement that tests the riskiest assumptions in a healthcare product before production code is written: the integration surface, the regulatory posture, the scope and ownership, the data and identity architecture, and the experience itself, tested with real users on a working prototype. The output is a build-ready package: costed, sequenced decisions a sponsor can act on, plus the designs and prototype a development team can build from.

How much does discovery cost, and does it really save money?

A discovery and solution-design engagement typically runs 6 to 12 weeks, a small fraction of the build cost. It saves money because a wrong decision caught in discovery costs a revised plan, while the same decision caught mid-build costs the code, schema, and time already committed on top of it, roughly an order of magnitude more.

Is the “10x” saving a real number?

It’s an order-of-magnitude rule of thumb, not a precise measurement. It reflects both Sidebench’s experience across engagements and the long-established software-engineering pattern that the cost to fix a decision grows by roughly 10x at each stage it survives. The exact multiple varies by project. The direction, later is more expensive, is consistent.

We already have an AI-built prototype. Do we still need discovery?

Usually yes, and often more than teams expect. A working prototype proves the interface, not the system. Discovery measures the gap between the demo and a production healthcare product: the HIPAA architecture, the integration a real customer requires, the regulatory posture, and the failure modes that only appear under real patient load.

How is discovery different from a product workshop?

A generic product workshop answers “who’s the user and what’s the job.” Healthcare discovery adds the questions that decide whether the product ships: which regulator cares, which EHR gates the launch, how patients are matched, and whose sign-off is on the critical path. It’s the healthcare-specific risk work a generic workshop skips.

Does discovery include design and user testing?

Yes, and it is the part teams underestimate. Discovery produces full UI designs for the v1 scope and an interactive prototype, and that prototype goes in front of real users before the build starts. What comes back from those sessions changes workflows and screens while a change still costs a design revision instead of a rebuild. It also tends to cut scope, because a step users never complete is a step you do not have to build.

What’s the biggest risk discovery catches?

The integration assumption. Teams routinely scope a build around an EHR or legacy data flow they assume is available, simple, or fast, and it isn’t. Caught in discovery it’s a footnote. Caught mid-build it’s a rebuild. It’s the single most consistent expensive surprise in healthcare technology.

Does discovery tell us whether our product is FDA-regulated?

Yes. Determining whether a product is Software as a Medical Device, and what claims pull it into FDA scope, is a core part of healthcare discovery. Finding this out after the build has started is one of the most expensive surprises in the industry, because SaMD status reshapes the documentation, testing, and release process from the first commit.

How long before we can start building?

For most builds, 6 to 12 weeks, depending on how complex the integration and regulatory surface is. That phase runs in parallel with early planning, so it rarely adds to the total timeline. It usually shortens it, by preventing the mid-build rework that blows timelines apart.

Can we run discovery ourselves?

If you have documented product requirements, technical documentation, and a finished design that real users have already tested, you have what discovery produces. If any of those three are open, an outside read is cheaper than the rework of getting them wrong. A partner who sells you discovery you don’t need isn’t worth trusting.

What do we walk away with?

Product and technical requirements; full UI designs and an interactive prototype tested with real users; an integration risk audit; a regulatory posture read; a prioritized v1 scope with a named owner; a data and identity architecture proposal; and an implementation plan with budget and timeline. A decision a board or budget committee can act on, and a package a development team can start from.

Who should own the discovery phase internally?

One named product owner with cross-functional authority to cut scope. The most reliable failure mode in healthcare builds is decision rights split across a sponsor, a clinical lead, and an IT lead who don’t yet agree. Discovery surfaces that split early and forces the ownership question while it’s still cheap to answer.

About the author

Cited sources

• HHS Office for Civil Rights, HIPAA Security Rule (45 CFR § 164.312)
• FDA, Digital Health Center of Excellence, AI-enabled device authorizations and 2025-2026 SaMD / change-control guidance
• Software-engineering cost-of-change escalation principle (order-of-magnitude increase per stage), as the established basis for the 10x framing